Photosensitizer Drug Market Revenue, Industry Growing Demand, Top Companies, Regional Outlook Up To 2031
The global photosensitizer drug market is expected to grow at a significant CAGR during the forecast period (2024-2031). In photodynamic therapy (PDT), photosensitizer medications or photosensitizing chemicals are utilized to treat cancer. When these compounds are exposed to a specific wavelength of light, an active form of oxygen is produced, which kills cancer cells nearby. Porphyrin derivatives, Aminolevulinic acid (ALA), chlorines, are some available porphyrin derivatives. Porphyrin derivative (PD), a first-generation photosensitizer, is effective in treating brain, lung, laryngeal, gastric, cutaneous, and esophageal carcinomas to a degree. Porfimer sodium, also known as Photofrin, is a photosensitizing compound used in PDT for the treatment of esophageal cancer and non-small cell lung cancer. Porphyrin-based second-generation photosensitizers include benzoporphyrins, texaphyrins, purpurins, naphthalocyanines, and phthalocyanines. 5-aminolevulinic acid (ALA) is another extensively used photosensitizer, which is mostly utilized for oral leukoplakia owing to the benefits of low-light dose.
Get Free Sample link @ https://www.omrglobal.com/request-sample/photosensitizer-drug-market
During the forecast period, rising cancer prevalence and the burden of dermatological conditions are expected to drive the global photosensitizer drug market. Head and neck cancer accounted for roughly 4% of all cancers in the US in 2017, according to the American Society of Clinical Oncology (ASCO). According to the estimate, nearly 65,000 people will suffer from head and neck cancer. The demand for photosensitizer medications is expected to rise in the near future as a result of this. Skin infections are quite frequent, ranking fourth among the most common ailments in the world. According to the World Health Organization (WHO), skin cancer accounts for one out of every three cancers diagnosed, and one out of every five Americans will acquire skin cancer during their lifetime, according to Skin Cancer Foundation statistics. The demand for photosensitizer drugs is projected to be driven by the baby boomer group, which is susceptible to a variety of cancers and skin problems.
Full report of Photosensitizer Drug Market available @ https://www.omrglobal.com/industry-reports/photosensitizer-drug-market
Market Coverage
Competitive Landscape: Galderma S.A., Biofrontera AG, Sun Pharmaceutical Industries Ltd., and Others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Photosensitizer Drug Market Report Segmentation
By Product
By Application
By End-User
Reasons to Buying From us -
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/photosensitizer-drug-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Please complete the following requested information to flag this post and report abuse, or offensive content. Your report will be reviewed within 24 hours. We will take appropriate action as described in Findit terms of use.